Risk of secondary hematological malignancies and hematological toxicities in recurrent ovarian cancer patients treated with poly adenosine diphosphate ribose polymerase (PARP) inhibitors maintenance

Category Systematic review
JournalAnnals of Oncology
Year 2018
This article has no abstract
Epistemonikos ID: fd5e55ff2b6e660aaf2376b3fb853f90ed492b0f
First added on: Feb 11, 2025